Enhancing uterine receptivity for embryo implantation through controlled collagenase intervention.


Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 13 02 2024
revised: 25 07 2024
accepted: 25 07 2024
medline: 17 8 2024
pubmed: 17 8 2024
entrez: 16 8 2024
Statut: epublish

Résumé

Ineffective endometrial matrix remodeling, a key factor in infertility, impedes embryo implantation in the uterine wall. Our study reveals the cellular and molecular impact of human collagenase-1 administration in mouse uteri, demonstrating enhanced embryo implantation rates. Collagenase-1 promotes remodeling of the endometrial ECM, degrading collagen fibers and proteoglycans. This process releases matrix-bound bioactive factors (e.g., VEGF, decorin), facilitating vascular permeability and angiogenesis. Collagenase-1 elevates embryo implantation regulators, including NK cell infiltration and the key cytokine LIF. Remarkably, uterine tissue maintains structural integrity despite reduced endometrial collagen fiber tension. In-utero collagenase-1 application rescues implantation in heat stress and embryo transfer models, known for low implantation rates. Importantly, ex vivo exposure of human uterine tissue to collagenase-1 induces collagen de-tensioning and VEGF release, mirroring remodeling observed in mice. Our research highlights the potential of collagenases to induce and orchestrate cellular and molecular processes enhancing uterine receptivity for effective embryo implantation. This innovative approach underscores ECM remodeling mechanisms critical for embryo implantation.

Identifiants

pubmed: 39151945
pii: 7/10/e202402656
doi: 10.26508/lsa.202402656
pii:
doi:

Substances chimiques

Collagenases EC 3.4.24.-
collagenase 1 EC 3.4.24.-
Vascular Endothelial Growth Factor A 0
Collagen 9007-34-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 Zehorai et al.

Auteurs

Eldar Zehorai (E)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.

Tamar Gross Lev (T)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.

Elee Shimshoni (E)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.

Ron Hadas (R)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.

Idan Adir (I)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.

Ofra Golani (O)

https://ror.org/0316ej306 Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.

Guillaume Molodij (G)

https://ror.org/0316ej306 Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.

Ram Eitan (R)

Gynecologic Oncology Division, Helen Schneider Hospital for Women, Rabin Medical Center; Petah-Tikva and The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Karl E Kadler (KE)

Wellcome Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.

Orit Kollet (O)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.

Michal Neeman (M)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.

Nava Dekel (N)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.

Inna Solomonov (I)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel inna.solomonov@weizmann.ac.il.

Irit Sagi (I)

https://ror.org/0316ej306 Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel irit.sagi@weizmann.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH